Lead Product(s) : Nicorandil
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Chugai Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts
Details : Nicorandil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Nicorandil
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Chugai Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicorandil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2017
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : JW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicorandil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2015
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : JW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
Details : Nicorandil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angina, Stable.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 20, 2011
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicorandil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angina, Stable.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2011
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicorandil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angina Pectoris.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2010
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicorandil
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicorandil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2010
Lead Product(s) : Nicorandil
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
